title: Primary diffuse large B-cell lymphoma associated with chronic osteomyelitis of the knee.
abstract: Diffuse large B-cell lymphoma (DLBCL) associated with chronic inflammation is a recently adopted category of DLBCL, which describes an aggressive B-cell lymphoma raised in the setting of non-immune chronic inflammation. Primary presentation of this subtype of DLBCL in bone is extremely rare. Here, we present the case of a 27 year old woman with DLBCL of the right distal femur, identified after a three-year history of chronic osteomyelitis. In this report, we describe the clinical and histopathologic features of this unusual presentation of DLBCL and discuss aspects relevant to diagnosis and treatment of this entity.
authors.affiliation: National Institute of Cancer, Bogota, Colombia.
authors.forename: Alfredo E
authors.initials: AE
authors.lastname: Romero-Rojas
authors.affiliation: University of California, San Diego, La Jolla, CA, United States; University of Santander, Bucaramanga, Colombia. Electronic address: jdiazperez@ucsd.edu.
authors.forename: Julio A
authors.initials: JA
authors.lastname: Diaz-Perez
authors.affiliation: University of California, San Diego, La Jolla, CA, United States.
authors.forename: Sharat
authors.initials: S
authors.lastname: Raju
authors.affiliation: National Institute of Cancer, Bogota, Colombia.
authors.forename: Oscar
authors.initials: O
authors.lastname: Messa-Botero
authors.affiliation: National Institute of Cancer, Bogota, Colombia.
authors.forename: Andres
authors.initials: A
authors.lastname: Prieto-Bletan
authors.affiliation: National Institute of Cancer, Bogota, Colombia.
authors.forename: Felipe
authors.initials: F
authors.lastname: Criollo-Palacios
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use; D004009:Dicloxacillin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005266:Femoral Neoplasms / Q000188:drug therapy / Q000473:pathology*; D004854:Herpesvirus 4, Human / Q000472:pathogenicity; D006801:Humans; D007719:Knee Joint / Q000000981:diagnostic imaging / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000473:pathology*; D010019:Osteomyelitis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D011859:Radiography; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D004009:Dicloxacillin; D011241:Prednisone
keywords: Bone neoplasm; Chronic inflammation; Chronic osteomyelitis; Diffuse large b-cell lymphoma; Epstein–Bar virus